Ratings Don’t Lie: Charles River (NYSE:CRL) Gets Better Rating From Barclays. What Is The Stock Target?

November 30, 2016 - By Louis Casey

Ratings Don't Lie:  Charles River (NYSE:CRL) Gets Better Rating From Barclays. What Is The Stock Target?

Charles River (NYSE:CRL) Upgrade

In a an analyst report revealed to investors on Wednesday, 30 November, investment analysts at Barclays’s equities division raised Charles River (NYSE:CRL)‘s stock from a “Underweight” to “Equal-Weight”.

Charles River Laboratories Intl. Inc (NYSE:CRL) Ratings Coverage

Out of 10 analysts covering Charles River Laboratories (NYSE:CRL), 4 rate it a “Buy”, 3 “Sell”, while 3 “Hold”. This means 40% are positive. $100 is the highest target while $65 is the lowest. The $82.88 average target is 15.82% above today’s ($71.56) stock price. Charles River Laboratories has been the topic of 18 analyst reports since August 3, 2015 according to StockzIntelligence Inc. On Tuesday, September 6 the stock rating was downgraded by UBS to “Sell”. The firm earned “Buy” rating on Tuesday, April 26 by Gabelli. The stock of Charles River Laboratories Intl. Inc (NYSE:CRL) earned “Outperform” rating by Wells Fargo on Thursday, January 7. The rating was maintained by Deutsche Bank on Friday, July 31 with “Hold”. The firm has “Buy” rating by Jefferies given on Friday, January 8. On Friday, January 8 the stock rating was maintained by Robert W. Baird with “Outperform”. The stock has “Buy” rating given by Jefferies on Thursday, August 4. Credit Suisse reinitiated Charles River Laboratories Intl. Inc (NYSE:CRL) on Friday, August 14 with “Neutral” rating. The stock has “Outperform” rating given by William Blair on Friday, August 28. As per Friday, May 20, the company rating was maintained by Barclays Capital.

It is down 12.23% since April 27, 2016 and is downtrending. It has underperformed by 17.46% the S&P500.

Analysts await Charles River Laboratories Intl. Inc (NYSE:CRL) to report earnings on February, 8. They expect $1.12 earnings per share, up 12.00% or $0.12 from last year’s $1 per share. CRL’s profit will be $53.06M for 15.97 P/E if the $1.12 EPS becomes a reality. After $1.18 actual earnings per share reported by Charles River Laboratories Intl. Inc for the previous quarter, Wall Street now forecasts -5.08% negative EPS growth.

Insitutional Activity: The institutional sentiment decreased to 0.95 in Q2 2016. Its down 0.48, from 1.43 in 2016Q1. The ratio worsened, as 25 funds sold all Charles River Laboratories Intl. Inc shares owned while 81 reduced positions. 39 funds bought stakes while 113 increased positions. They now own 44.08 million shares or 4.37% less from 46.09 million shares in 2016Q1.

Teacher Retirement Systems Of Texas, a Texas-based fund reported 6,533 shares. Legal General Gp Public Ltd Company holds 0% of its portfolio in Charles River Laboratories Intl. Inc (NYSE:CRL) for 5,477 shares. Fmr Ltd Liability Corp accumulated 0.02% or 2.16M shares. Ameritas Investment Prtnrs Inc has 0.04% invested in the company for 7,460 shares. Blackrock Ltd has 0% invested in the company for 56,734 shares. Nordea Investment Mngmt reported 33,697 shares or 0.01% of all its holdings. Jp Marvel Invest Advsrs Llc holds 0.41% or 14,130 shares in its portfolio. Moreover, State Of Wisconsin Board has 0.01% invested in Charles River Laboratories Intl. Inc (NYSE:CRL) for 30,415 shares. Pnc Fincl Svcs Group holds 3,787 shares or 0% of its portfolio. Raymond James & Associates reported 24,969 shares or 0.01% of all its holdings. Cornercap Investment Counsel holds 0.11% or 7,070 shares in its portfolio. Piermont Management holds 14,919 shares or 0.32% of its portfolio. Copper Rock Ptnrs Lc last reported 240,615 shares in the company. Pembroke Management Limited holds 317,435 shares or 2.39% of its portfolio. Century Cap Management Limited Com has 151,053 shares for 1.38% of their US portfolio.

Insider Transactions: Since July 1, 2016, the stock had 0 buys, and 7 sales for $4.75 million net activity. 7,877 Charles River Laboratories Intl. Inc (NYSE:CRL) shares with value of $662,446 were sold by Molho Davide. On Friday, August 5 FOSTER JAMES C sold $1.13M worth of the stock or 13,175 shares. On Monday, November 28 REESE C RICHARD sold $326,485 worth of the stock or 4,539 shares. Shares for $66,831 were sold by MASSARO GEORGE. On Friday, July 29 WALLMAN RICHARD F sold $681,120 worth of the stock or 7,740 shares.

Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The company has a market cap of $3.39 billion. The Firm is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. It has a 24.02 P/E ratio. The Firm operates through three divisions: Research Models and Services , which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

According to Zacks Investment Research, “Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies and has been in this business for more than 50 years.”

CRL Company Profile

Charles River Laboratories International, Inc., incorporated on February 3, 1994, is a full service, early-stage contract research company. The Firm is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Firm operates through three divisions: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). It develops a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development. It also provides a suite of services and products to support its clients’ manufacturing activities.

Another recent and important Charles River Laboratories Intl. Inc (NYSE:CRL) news was published by Benzinga.com which published an article titled: “Benzinga’s Top Upgrades” on November 30, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>